Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 1,800 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were bought at an average price of $6.13 per share, for a total transaction of $11,034.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,812,669.63. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 24th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were bought at an average price of $6.24 per share, for a total transaction of $62,400.00.
  • On Wednesday, August 23rd, Phillip Md Et Al Frost bought 12,000 shares of Opko Health stock. The shares were bought at an average price of $6.13 per share, for a total transaction of $73,560.00.
  • On Monday, August 21st, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The shares were bought at an average price of $6.10 per share, for a total transaction of $152,500.00.
  • On Thursday, August 17th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were bought at an average price of $5.96 per share, for a total transaction of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost bought 40,000 shares of Opko Health stock. The shares were bought at an average price of $6.04 per share, for a total transaction of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The shares were bought at an average price of $6.08 per share, for a total transaction of $152,000.00.
  • On Monday, August 14th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were bought at an average price of $6.15 per share, for a total transaction of $61,500.00.
  • On Friday, August 11th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were bought at an average price of $6.19 per share, for a total transaction of $61,900.00.
  • On Thursday, August 10th, Phillip Md Et Al Frost bought 39,000 shares of Opko Health stock. The shares were bought at an average price of $6.23 per share, for a total transaction of $242,970.00.
  • On Wednesday, August 9th, Phillip Md Et Al Frost bought 18,000 shares of Opko Health stock. The shares were bought at an average price of $6.35 per share, for a total transaction of $114,300.00.

Shares of Opko Health, Inc. (NASDAQ OPK) traded down 1.75% during midday trading on Friday, hitting $6.19. The company had a trading volume of 1,439,946 shares. The stock has a 50 day moving average price of $6.24 and a 200 day moving average price of $7.12. Opko Health, Inc. has a 1-year low of $5.85 and a 1-year high of $12.15. The firm’s market capitalization is $3.46 billion.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.02 earnings per share. On average, equities analysts anticipate that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/25/phillip-md-et-al-frost-purchases-1800-shares-of-opko-health-inc-opk-stock.html.

Several equities research analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on Opko Health in a research report on Thursday, August 17th. They set an “overweight” rating and a $20.00 target price on the stock. Zacks Investment Research downgraded Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reiterated a “hold” rating and issued a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Barrington Research increased their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and an average price target of $15.28.

Several institutional investors have recently bought and sold shares of OPK. Financial Architects Inc increased its position in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 4,800 shares in the last quarter. AQR Capital Management LLC acquired a new position in Opko Health during the fourth quarter valued at $105,000. Blair William & Co. IL acquired a new position in Opko Health during the second quarter valued at $112,000. Timber Hill LLC acquired a new position in Opko Health during the first quarter valued at $114,000. Finally, Engineers Gate Manager LP acquired a new position in Opko Health during the second quarter valued at $117,000. 22.94% of the stock is currently owned by hedge funds and other institutional investors.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.